Cytek Biosciences Inc (CTKB)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 62.90% | 54.92% | 54.97% | 55.48% | 56.69% | 57.75% | 60.05% | 61.32% | 61.56% | 61.60% | 60.45% | 61.22% | 61.94% | 62.72% | 62.77% | 58.33% | 55.70% |
| Operating profit margin | -11.62% | -11.75% | -13.06% | -13.16% | -14.43% | -15.09% | -10.65% | -6.30% | -0.41% | 0.37% | 0.78% | 4.22% | 7.30% | 13.28% | 17.69% | 15.64% | 14.71% |
| Pretax margin | -3.23% | -5.92% | -8.22% | -7.80% | -8.14% | -8.58% | -5.51% | -2.70% | 0.77% | -1.55% | -1.35% | 1.92% | 4.79% | 11.42% | 16.59% | 15.38% | 15.54% |
| Net profit margin | -3.41% | -5.05% | -8.88% | -5.73% | -6.29% | -7.71% | -3.42% | -1.33% | 1.49% | -0.56% | -0.63% | 1.68% | 3.59% | 8.33% | 13.51% | 20.53% | 20.91% |
Based on the provided data for Cytek Biosciences Inc, the profitability ratios exhibit varying trends over the period from December 31, 2020, to December 31, 2024:
1. Gross Profit Margin:
- The gross profit margin shows a fluctuating pattern, starting at 55.70% in December 2020 and reaching a peak of 62.90% in December 2024. However, there is a decline in the gross profit margin from June 2023 onwards, dropping to 54.92% by September 2024.
2. Operating Profit Margin:
- The operating profit margin initially improves from 14.71% in December 2020 to 17.69% in June 2021. However, it experiences a sharp decline thereafter, turning negative from March 2022 onwards. By December 2024, the operating profit margin stands at -11.62%.
3. Pretax Margin:
- The pretax margin also follows a similar trend as the operating profit margin, with a steady decline over the period. It starts at 15.54% in December 2020, turns negative from June 2022, and continues to decrease, reaching -3.23% by December 2024.
4. Net Profit Margin:
- The net profit margin reflects a downward trajectory, declining from 20.91% in December 2020 to -3.41% in December 2024. There is a significant decrease in profitability from June 2023 onwards, with negative margins reported in subsequent periods.
Overall, the profitability ratios of Cytek Biosciences Inc demonstrate a deteriorating financial performance in terms of operational efficiency and ability to generate profits over the analyzed period. The declining trend in profitability margins, particularly in operating profit and net profit margins, highlights potential challenges faced by the company in maintaining profitability and efficiency in its operations.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -4.11% | -4.81% | -5.34% | -5.37% | -5.60% | -5.32% | -3.56% | -2.00% | -0.13% | 0.12% | 0.23% | 1.20% | 2.01% | 3.50% | 8.48% | 6.91% | 6.21% |
| Return on assets (ROA) | -1.21% | -2.07% | -3.63% | -2.34% | -2.44% | -2.72% | -1.14% | -0.42% | 0.47% | -0.17% | -0.19% | 0.48% | 0.99% | 2.19% | 6.48% | 9.08% | 8.82% |
| Return on total capital | -5.19% | -4.01% | -4.97% | -4.70% | -4.65% | -3.21% | -1.71% | -0.43% | 0.90% | 0.14% | 0.15% | 1.24% | 2.04% | 3.63% | — | — | — |
| Return on equity (ROE) | -1.52% | -2.64% | -4.51% | -2.93% | -3.09% | -3.40% | -1.41% | -0.52% | 0.57% | -0.21% | -0.23% | 0.57% | 1.13% | 2.47% | — | — | — |
Cytek Biosciences Inc's profitability ratios indicate a declining trend over the years.
1. Operating Return on Assets (Operating ROA) has decreased from 6.21% in December 2020 to -5.60% in December 2023, showing a deterioration in the company's ability to generate profits from its assets through core operations.
2. Return on Assets (ROA) also showcases a negative trend, declining from 8.82% in December 2020 to -1.21% in December 2024, indicating a reduction in overall profitability relative to the total assets employed.
3. Return on Total Capital was not available for the initial periods but started declining from 3.63% in September 2021 to -5.19% in December 2024, signifying a diminishing return on the total capital invested in the business over time.
4. Return on Equity (ROE) data was inaccessible initially, and when available, it decreased from 2.47% in September 2021 to -1.52% in December 2024, displaying a negative return to equity holders in the latter years.
Overall, the declining profitability ratios suggest challenges in generating returns from assets, total capital, and shareholders' equity, pointing towards potential operational and financial concerns within Cytek Biosciences Inc.